MedTrace Logo

Midodrine Hydrochloride in Early Sepsis

NCT03129542 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-02-05

No results posted yet for this study

Summary

The investigators would like to determine if early administration of oral Midodrine in participants diagnosed with sepsis will impact blood pressures and decrease the need for and/or doses of intravenous pressor agents.

Conditions

Interventions

DRUG

Midodrine Hydrochloride 10 milligrams

Three doses taken every 8 hours.

DRUG

Placebo capsule

Three doses taken every 8 hours.

Sponsors & Collaborators

  • Cleveland Clinic Abu Dhabi

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Ognjen Gajic · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-30
Primary Completion
2020-04-28
Completion
2020-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129542 on ClinicalTrials.gov